3 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 3 of 3 clinical reviews.
A clinician-reviewed guide to sirolimus pharmacogenomics, dosing, and safety considerations specific to Hispanic and Latino patients, covering CYP3A5 variants, diabetes risk, dyslipidemia, and ethnicity-stratified trial data.
Evidence-based review of how rapamycin (sirolimus) performs differently in South Asian populations, covering pharmacogenomics, CYP3A5 polymorphisms, metabolic context, and dosing adjustments.
South Asian patients face distinct pharmacogenomic and metabolic risks with sirolimus. Learn how CYP3A5 expression, baseline insulin resistance, and cardiovascular risk at lower BMI affect dosing, monitoring, and safety thresholds for rapamycin in this population.